Mechanistic evaluation of pachymic acid in breast cancer via network pharmacology and in vitro validation
Yibing Zhou, Zhuotao Yang, Yuchen Duan, Yijie Cheng, Wenqian Xu, Bo Wang, Jingyuan Xu, Da Qian, Chaoshen Wu · 2026
Read Mechanistic evaluation of pachymic acid in breast cancer via network pharmacology and in vitro validation by Yibing Zhou, Zhuotao Yang, Yuchen Duan, Yijie Cheng, Wenqian Xu, Bo Wang, Jingyuan Xu, Da Qian, Chaoshen Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471631.txt.
Description
Zhou and co-authors used network pharmacology, computational target fishing, to predict how pachymic acid, a fungus-derived compound, attacks triple-negative breast cancer, then checked the predictions in cells. Their 2026 study screened drug and disease databases, filtered hits through cancer survival data, and landed on three key targets: PTGS2, NOS2, and ABCB1.
In MDA-MB-231 cells, the standard triple-negative model, pachymic acid significantly cut proliferation, migration, and invasion in dose tests, and raised lipid peroxidation, a marker of oxidative damage, in treated cells. Docking simulations supported direct binding to the predicted targets. The authors note the stakes: about one million new breast cancer cases arise yearly, nearly 18% of all female cancers, and five-year survival sits under 40% in developing regions.
Catalog record
| CREATOR | Yibing Zhou, Zhuotao Yang, Yuchen Duan, Yijie Cheng, Wenqian Xu, Bo Wang, Jingyuan Xu, Da Qian, Chaoshen Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |